USA - NASDAQ:AMGN - US0311621009 - Common Stock
Overall AMGN gets a fundamental rating of 5 out of 10. We evaluated AMGN against 534 industry peers in the Biotechnology industry. While AMGN has a great profitability rating, there are quite some concerns on its financial health. AMGN may be a bit undervalued, certainly considering the very reasonable score on growth AMGN also has an excellent dividend rating.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.53% | ||
| ROE | 89.11% | ||
| ROIC | 14.12% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.3% | ||
| PM (TTM) | 18.96% | ||
| GM | 69.71% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.24 | ||
| Debt/FCF | 4.94 | ||
| Altman-Z | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.38 | ||
| Fwd PE | 13.26 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.8 | ||
| EV/EBITDA | 12.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.25% |
291.77
-0.32 (-0.11%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.25% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.38 | ||
| Fwd PE | 13.26 | ||
| P/S | 4.5 | ||
| P/FCF | 13.8 | ||
| P/OCF | 13.08 | ||
| P/B | 21.15 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.43 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.53% | ||
| ROE | 89.11% | ||
| ROCE | 16.21% | ||
| ROIC | 14.12% | ||
| ROICexc | 16.03% | ||
| ROICexgc | 59.12% | ||
| OM | 31.3% | ||
| PM (TTM) | 18.96% | ||
| GM | 69.71% | ||
| FCFM | 32.61% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.24 | ||
| Debt/FCF | 4.94 | ||
| Debt/EBITDA | 3.25 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.72% | ||
| Profit Quality | 172.01% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | N/A |
ChartMill assigns a fundamental rating of 5 / 10 to AMGN.
ChartMill assigns a valuation rating of 7 / 10 to AMGEN INC (AMGN). This can be considered as Undervalued.
AMGEN INC (AMGN) has a profitability rating of 7 / 10.
The Price/Earnings (PE) ratio for AMGEN INC (AMGN) is 13.38 and the Price/Book (PB) ratio is 21.15.
The financial health rating of AMGEN INC (AMGN) is 3 / 10.